Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02621151
Title Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Chicago Chicago Illinois 60637 United States Details
University of Michigan Health System Ann Arbor Michigan 48109 United States Details
NYU Perlmutter Cancer Center New York New York 10016 United States Details
Memorial Sloan Kettering New York New York 10065 United States Details
University of North Carolina Chapel Hill North Carolina 27599-7305 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field